摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-amino-6-methoxybenzo[e][1,2,4]triazine 1-oxide | 492469-55-3

中文名称
——
中文别名
——
英文名称
3-amino-6-methoxybenzo[e][1,2,4]triazine 1-oxide
英文别名
3-amino-6-methoxy-1,2,4-benzotriazine 1-oxide;6-methoxy-1,2,4-benzotriazin-3-amine 1-oxide;6-Methoxy-1-oxido-1,2,4-benzotriazin-1-ium-3-amine
3-amino-6-methoxybenzo[e][1,2,4]triazine 1-oxide化学式
CAS
492469-55-3
化学式
C8H8N4O2
mdl
——
分子量
192.177
InChiKey
UHEMGSPHLDOGOM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    86.5
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-amino-6-methoxybenzo[e][1,2,4]triazine 1-oxidecopper(l) iodide 亚硝酸特丁酯 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以62%的产率得到3-iodo-6-methoxy-1,2,4-benzotriazine 1-oxide
    参考文献:
    名称:
    Stille Coupling Reactions in the Synthesis of Hypoxia-Selective 3-Alkyl-1,2,4-Benzotriazine 1,4-Dioxide Anticancer Agents
    摘要:
    The introduction of a 3-alkyl substituent is a key step in the synthesis of 1,2,4-benzotriazine 1,4-dioxide hypoxia-selective anticancer agents, such as SN29751. The Stille reaction of 3-chloro-1,2,4-benzotriazine 1-oxides ( BTOs) 5 was inhibited by the presence of electron donating substituents on the benzo ring, thus limiting the range of compounds available for SAR studies. The use of 3-iodo-BTOs 8 did not provide a significant improvement in the yields of 3-ethyl-BTOs 6. Microwave-assisted Stille coupling of chlorides 5 gave dramatically improved yields, which were consistently superior to those from the corresponding iodides 8. The application of microwave-assisted synthesis extended the range of substituted BTOs available for SAR studies and provided an efficient, scalable synthesis of the investigational anticancer agent, SN29751 ( 1).
    DOI:
    10.1021/jo060986g
  • 作为产物:
    描述:
    参考文献:
    名称:
    1,2,4-苯并三嗪1,4-二氧化物作为替拉帕明的低氧选择性类似物的构效关系。
    摘要:
    替拉帕明(TPZ,1,2,4-苯并三嗪-3-胺1,4-二氧化物)是一种生物还原性低氧细胞毒素,目前在II / III期临床试验中结合放疗和基于顺铂的化学疗法。作为开发具有改善的溶解度/效能和治疗指数的TPZ类似物的程序的一部分,我们合成了34 1,2,4-苯并三嗪-3-胺1,4-二氧化物(BTO),以检查其结构活性关系(SAR)。环取代。系统地改变了5、6、7和8位上取代基的电子,疏水和空间参数,并确定了类似物的水溶性和单电子还原电位[E(1)] 。对于每种化合物,我们通过克隆形成存活率确定了有氧和低氧条件下小鼠SCCVII肿瘤细胞的体外杀伤作用,并确定了它们的相对低氧毒性(RHT;相对于TPZ)和低氧细胞毒性比(HCR)。使用96孔SRB增殖测定法独立评估了化合物的子集,其数据与克隆形成终点所得出的数据具有良好的相关性。除5-和8-二甲基氨基和8-二乙基氨基外,大多数取代基的溶解度均低于TPZ。E(1)值的范围是-240
    DOI:
    10.1021/jm020367+
点击查看最新优质反应信息

文献信息

  • Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
    申请人:Auckland Uniservices Limited
    公开号:EP1468688A2
    公开(公告)日:2004-10-20
    The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy. The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.
    本发明涉及一种协同组合物,包括一种或多种苯并噁唑-单-N-氧化物,以及一种或多种苯并噁唑1,4-二氧化物,用于癌症治疗。 该发明还提供了一系列新颖的1,2,4苯并噁唑-单-N-氧化物及相关类似物。这些可以用作增强现有抗癌药物的细胞毒性和癌症治疗的治疗剂。
  • [EN] NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES<br/>[FR] 1,2,4-BENZOTRIAZINE-1,4-DIOXYDES
    申请人:AUCKLAND UNISERVICES LTD
    公开号:WO2005082867A1
    公开(公告)日:2005-09-09
    The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours, to their preparation, and to their use as hypoxia-selective cytotoxic drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    本发明提供了一种简化的特征集,可用于选择对人类肿瘤异种移植物中的缺氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),并进一步提供了一种新型的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),预测其对肿瘤的体内活性,以及它们的制备和用作缺氧选择性细胞毒药物和放射增敏剂用于癌症治疗,单独或与放射线和/或其他抗癌药物结合使用。
  • Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity
    作者:Folkert Reck、Richard Alm、Patrick Brassil、Joseph Newman、Boudewijn DeJonge、Charles J. Eyermann、Gloria Breault、John Breen、Janelle Comita-Prevoir、Mark Cronin、Hajnalka Davis、David Ehmann、Vincent Galullo、Bolin Geng、Tyler Grebe、Marshall Morningstar、Phil Walker、Barry Hayter、Stewart Fisher
    DOI:10.1021/jm2008826
    日期:2011.11.24
    isolates, but suffer from potent hERG inhibition (IC50= 3 μM for 1). We now disclose the finding that new analogues of 1 with an N-linked cyclic amide moiety attached to the ethyl bridge, such as 24m, retain the broad-spectrum antibacterial activity of 1 but show significantly less hERG inhibition (IC50= 31 μM for 24m) and higher free fraction than 1. One optimized analogue, compound 24l, showed moderate
    新型的细菌II型拓扑异构酶的非氟喹诺酮抑制剂(DNA促旋酶和拓扑异构酶IV)对于开发不受靶标介导的氟喹诺酮类交叉耐药性影响的新型抗菌剂具有重要意义。具有通过碳与乙基桥连接的双环芳族部分的氨基哌啶,例如1,通常显示出强效的广谱抗菌活性,包括对喹诺酮类耐药的菌株,但受到强的hERG抑制作用(IC 50 = 3μM/ 1) 。我们现在公开的发现是,新的1的类似物具有连接到乙基桥的N-连接的环状酰胺部分,例如24m,保留了其的广谱抗菌活性。1,但显示出显着更少的hERG抑制作用(24 m时IC 50 = 31μM)和高于1的游离分数。一种优化的类似物化合物24l在狗的大腿感染模型中在狗中表现出中等清除率,并且有望抵抗金黄色葡萄球菌。
  • Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides
    作者:Robert F. Anderson、Sujata S. Shinde、Michael P. Hay、Swarna A. Gamage、William A. Denny
    DOI:10.1039/b502586a
    日期:——
    following the one-electron reduction of tirapazamine and its elimination of water from the initial reduction intermediate, and have suggested that this species is a cytotoxin. In this paper we have used pulse radiolysis to measure the one-electron reduction potentials of the benzotriazinyl radicals E(B*,H(+)/B) of 30 analogues of tirapazamine as well as the one-electron reduction potentials of their two-electron
    揭示抗癌药物替拉帕明(3-氨基-1,2,4-苯并三嗪1,4-二氧化物)引起缺氧选择性细胞毒性的自由基机制,被视为开发临床上有用的针对化学疗法的生物还原药物的方法。和耐辐射的缺氧肿瘤细胞。我们以前的研究指出,单电子还原替拉帕明并从初始的还原中间体中除去水后,会形成一个活性的苯并三嗪基自由基,并表明该物种是一种细胞毒素。在本文中,我们使用脉冲辐解法测量了替拉帕明的30个类似物的苯并三嗪基自由基E(B *,H(+)/ B)的单电子还原电势以及它们的两个电子还原的代谢物,苯并三嗪1氧化物E(B / B *-)。发现主要通过苯并三嗪1的单电子还原电位来追踪单电子还原的1,3-二氧化苯并三嗪1,4-二氧化物被氧反氧化的氧化还原依赖性,自由基的质子性和除水反应。 ,4-二氧化物E(A / A *-)。对已发表的SCCVII鼠肿瘤细胞系需氧和低氧克隆性细胞毒性数据进行多元回归分析,并在此研究中测量其物理化
  • Novel 1,2,4-benzotriazine-1,4-dioxides
    申请人:Denny Alexander William
    公开号:US20070197534A1
    公开(公告)日:2007-08-23
    The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours, to their preparation, and to their use as hypoxia-selective cytotoxic drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    本发明提供了一组简化的特征,可用于选择对人类肿瘤异种移植物中的低氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物化合物(TPZ类似物),并进一步提供一种新型的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),预测其对肿瘤的体内活性,以及它们的制备和作为低氧选择性细胞毒性药物和放射增敏剂用于癌症治疗,单独或与放射线和/或其他抗癌药物联合使用。
查看更多